All‐cause mortality at 100 days post‐transplant · Patients undergoing stem cell transplant with malignant and non‐malignant diseases
Summary of findings: Ursodeoxycholic acid may leads to lower all‐cause mortality at 100 days post‐transplant ( compared with placebo or no treatment (low certainty).
1 finding from 1 review
All‐cause mortality at 100 days post‐transplant · Patients undergoing stem cell transplant with malignant and non‐malignant diseases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality at 100 days post‐transplant · Patients undergoing stem cell transplant with malignant and non‐malignant diseases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality at 100 days post‐transplant · Patients undergoing stem cell transplant with malignant and non‐malignant diseases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality at 100 days post‐transplant · Patients undergoing stem cell transplant with malignant and non‐malignant diseases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality at 100 days post‐transplant · Patients undergoing stem cell transplant with malignant and non‐malignant diseases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality at 100 days post‐transplant · People undergoing autologous or HLA identical allogeneic bone marrow transplant with a variety of malignant diseases or aplastic anaemia
Summary of findings: Heparin showed no clear difference in all‐cause mortality at 100 days post‐transplant ( compared with no treatment (low certainty).
1 finding from 1 review
Change in severity of overall symptoms: intermediate‐term (3 to 4 days) Subjective severity score · patients with common cold
Antihistamines showed no clear difference in change in severity of overall symptoms: intermediate‐term (3 to 4… compared with placebo (high certainty).
1 finding from 1 review
Change in severity of overall symptoms: long‐term (6 to 10 days) Subjective severity score · patients with common cold
Antihistamines showed no clear difference in change in severity of overall symptoms: long‐term (6 to 10 days)… compared with placebo (high certainty).
1 finding from 1 review
Change in severity of overall symptoms: short‐term (1 to 2 days) Subjective severity score · patients with common cold
Sedating antihistamines leads to lower change in severity of overall symptoms: short‐term (1 to 2 days)… compared with placebo (high certainty).
1 finding from 1 review
Change in severity of overall symptoms: long‐term (6 to 10 days) Subjective severity score · patients with common cold
Sedating antihistamines showed no clear difference in change in severity of overall symptoms: long‐term (6 to 10 days)… compared with placebo (high certainty).
1 finding from 1 review
Perinatal mortality (stillbirth ‐ death of fetus prior to birth; neonatal death ‐ death within the first 28 days of birth; or infant death ‐ death after the first 28 days) · pregnant women with a term suspected compromised baby
1 finding from 1 review
Intervention not reported
Number of subjects who develop any adverse event (42 days to 10 months) · adults with asymptomatic bacteriuria
The intervention probably leads to higher number of subjects who develop any adverse event (42 days to 10… (moderate certainty).
1 finding from 1 review
Intervention not reported
Number of subjects with bacteriological cure (42 days to 4 years) · adults with asymptomatic bacteriuria
The intervention probably leads to higher number of subjects with bacteriological cure (42 days to 4 years) (moderate certainty).
1 finding from 1 review
30‐Day mortality · Patients with hip fracture repair
Liberal showed no clear difference in 30‐day mortality compared with restrictive threshold transfusion (low certainty).
1 finding from 1 review
Physician's assessment of global response of improvement, clear or excellent ‐ 6 weeks · people with atopic dermatitis
Tacrolimus 0.03% probably leads to higher physician's assessment of global response of improvement, clear or… compared with corticosteroids (moderate certainty).
4 findings from 1 review
RR 2.05 [1.36, 3.08]
1 study · 411 participants
Moderate
RR 2.58 [1.96, 3.38]
2 studies · 790 participants
Moderate
RR 0.45 [0.13, 1.57]
2 studies · 409 participants
Very low
Show 1 more finding
Participant's self‐assessment of global response of improvement: tacrolimus 0.03% 2x/day versus hydrocortisone acetate 1% 2x/day · people with atopic dermatitis
Tacrolimus 0.03% probably leads to higher participant's self‐assessment of global response of improvement:… compared with corticosteroids (moderate certainty).
1 finding from 1 review
Infant death (up to 175 days) · Pregnant women aged 18 to 38 years and an estimated gestation of 20 to 36 weeks.
Viral influenza vaccine showed no clear difference in infant death (up to 175 days) compared with control (moderate certainty).
1 finding from 1 review
Neonatal hospitalisation due to sepsis within 28 days of birth · Pregnant women aged 18 to 38 years and an estimated gestation of 20 to 36 weeks.
Viral influenza vaccine showed no clear difference in neonatal hospitalisation due to sepsis within 28 days of birth compared with control (moderate certainty).
1 finding from 1 review
Neonatal mortality · Women receiving supplements in pregnancy
It is very uncertain whether any intermittent iron regimen (with or without other vitamins and… changes neonatal death (within 28 days after delivery) compared with daily regimen (with same vitamins and minerals)‐infant outcomes (very low certainty).
1 finding from 1 review